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PROGNOSTIC FACTORS AND SURVIVAL 
IN PATIENTS WITH BRAIN METASTASES
Emily Frinton1 and Ruth Board2
1University of Manchester, Manchester, U.K.;
2Lancashire Teaching Hospitals NHS Foundation Trust, U.K.
Background: Brain metastases from malignant melanoma carry
a poor prognosis. Novel systemic agents have improved overall
survival (OS) but the value of whole-brain radiotherapy
(WBRT) and stereotactic radiosurgery (SRS) remains uncertain
(Dyer et al 2014). The melanoma-specific graded prognostic
assessment (msGPA) provides useful prognostic information
but the relevance to the modern-day population has not been
validated (1). Aims: Validation of the msGPA and the role of
SRS combined with other treatment versus WBRT alone.
Patients and Methods: Since 2011, 48 patients received
treatment for brain metastases from malignant melanoma at the
Rosemere Cancer Centre medical oncology clinic. Data were
collated on demographic factors and survival. Survival analyses
were performed using Kaplan–Meier methods. Cox regression
was used to identify prognostic factors on univariate and
multivariate analysis. Results: OS from the date of diagnosis
of brain metastases was 6.07 months (95% CI=2.13-10.0). On
univariate analysis, BRAF, performance status and msGPA
were significant prognostic indicators for OS (p=0.0086,
p=0.0014 and p=0.0001 respectively) and remained significant
on multivariate analysis. OS for BRAF-positive treated patients
(n=21) was 8.2 months, versus 3.7 months for BRAF-negative
patients (n=23). SRS combined with systemic agents (n=16)
produced an OS of 13.5 months.  Patients receiving WBRT
alone (n=12) had a poor prognosis (1.6 months). Discussion
and Conclusion: The msGPA remains a valid prognostic
indicator in the era of novel systemic treatments for melanoma.
Incorporation of BRAF-status may produce a model with even
greater prognostic discrimination. WBRT alone has no role in
the active management of melanoma brain metastases.
1 Wilkins A, Furness A, Corbett RW, Bloomfield A, Porta N,
Morris S, Ali Z, Larkin J and Harrington K: The
melanoma-specific graded prognostic assessment does not
adequately discriminate prognosis in a modern population
with brain metastases from malignant melanoma. Br J
Cancer 113(9): 1275-1281, 2015.
2 Dyer MA, Arvold ND, Chen YH, Pinnell NE, Mitin T, Lee
EQ, Hodi FS, Ibrahim N, Weiss SE, Kelly PJ, Floyd SR,
Mahadevan A and Alexander BM: The role of whole brain
radiation therapy in the management of melanoma brain
metastases. Radiat Oncol 9: 143, 2014.
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Introduction
In this edition of Anticancer Research, we present selected abstracts from the 6th International Student Cancer Conference held at
the Christie School of Oncology, Manchester UK, on September 24th and 25th 2016. Emily Frinton, from the University of
Manchester, UK, presented an updated evaluation of the melanoma-specific graded prognostic assessment (msGPA) since the clinical
development of BRAF inhibitors, to a modern-day population of 48 patients with brain metastases from melanoma treated with
radiotherapy. This study found that the msGPA still has prognostic utility and that incorporation of BRAF status may improve the
prognostic utility of this approach. Jolanda Schoon, from the University of Sheffield, UK, presented an analysis of the effect of 12
single nucleotide polymorphisms in DNA damage repair genes (XRCC2 and XRCC3) on survival in 1,076 patients with metastatic
colorectal cancer treated within the FOCUS clinical trial. This study found that an XRCC2 heterozygote and homozygote genotypes
of SNP rs3218408 were associated improved survival in this group of patients. Finally, Sheba Macheka of the University of Newcastle,
UK, presented the development of a novel immunofluorescent assay for the detection of circulating tumour cells (CTCs) from patients
with hepatocellular carcinoma (HCC), exploiting the expression of the HCC specific marker asialoglycoprotein receptor-1 by CTCs.
CTCs identified with this approach expressed both epithelial and mesenchymal markers. All the student presentations were of high
quality and we anticipate the next International Student Cancer Conference will be equally successful.
1University of Sheffield, Sheffield, U.K.;
2University of Leeds, Leeds, U.K.;
3Medical Research Council Clinical Trials Unit at UCL,
London, U.K.
4St. James University Hospital, Leeds, U.K.
Background: The FOCUS study aimed to determine the most
effective use of chemotherapeutics Irinotecan and Oxaliplatin.
The genetic factors influencing response to these drugs are
complex. Of particular interest are DNA damage repair genes.
This project explores common variants within two such genes:
XRCC2 and XRCC3. Aims: To test the hypothesis that 12
inherited genetic variants (single nucleotide polymorphisms;
SNP) in XRCC2 and XRCC3 are associated with survival in
patients with metastatic colorectal cancer. Methods: Analyses
focused on effects of SNP genotype and interaction with
treatment, on failure-free survival during the trial and overall
survival, using Kaplan–Meier curves and a Cox proportional-
hazards regression model. SNP data were available from 1,076
subjects. Results: Both the heterozygote and rare homozygote
genotypes of SNP rs3218408 in the XRCC2 gene were
associated with statistically significant improved survival in the
trial, with hazard ratios (HR) and 95% confidence intervals
(95% CI) of 0.86 (0.75-0.99) and 0.70 (0.53-0.93) respectively;
Ptrend=0.036. These effects remained significant after
controlling for treatment group (Ptrend=0.024). The heterozygote
genotype for SNP rs861528 was associated with statistically
significant poorer prognosis, but there was no effect of the rare
homozygote genotype. There was no evidence for interaction
between SNPs and treatment group. SNPs rs3218454 and
rs3218536 yielded statistically significant improved survival
when the treatment was 5-fluorouracil and irinotecan and 5-
fluorouracil and oxaliplatin respectively from the start.
Discussion: Results from these experiments show trends
between genetic variants and overall survival from metastatic
CRC. These results require validation in independent datasets.
Key Words: Fluorouracil, oxaliplatin, irinotecan, metastatic
colorectal cancer.
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THE ISOLATION AND CHARACTERISATION OF
CIRCULATING TUMOUR CELLS FROM PATIENTS
WITH HEPATOCELLULAR CARCINOMA
Sheba Macheka, David Jamieson, 
Helen Reeves and Misti Mccain
University of Newcastle, Newcastle, U.K.
Background: Hepatocellular carcinoma (HCC) is the second
most common cause of cancer-related mortality. The
characterization of circulating tumour cells (CTCs) from
peripheral blood, may provide information that may help predict
prognosis or stratify patients for targeted therapies.
Asialoglycoprotein receptor-1 (ASGPR1) is predominantly
expressed by hepatocytes and this may be utilised as a
biomarker to detect liver-specific CTCs. Some CTCs undergo
the epithelial-to-mesenchymal-transition (EMT) and express
Vimentin. This additional biomarker could aid with identifying
CTCs. Aims: To detect CTCs in blood samples from patients
with HCC, by targeting cells expressing ASGPR1 or Vimentin
using imagestreamX flow cytometry. Materials and Methods:
Blood samples were obtained from 8 consenting patients with
HCC. Red blood cells and leucocytes were depleted, in order to
enrich for CTCs. Following this, patient samples were stained
with a panel of antibodies conjugated with fluorochromes, in
order to identify Vimentin, Cytokeratin or ASGPR1 positive
CTCs using ImagestreamX. Furthermore, CTC detection was
based on additional parameters such as surface area (>200
μm2), the absence of CD45+ expression and a large nuclear
content. Results: ASGPR1 and Cytokeratin were the most
common biomarkers expressed by CTCs detected in 5 out of 8
of patients.  A greater number of CTCs detected, expressed only
vimentin compared to cytokeratin. This confirmed that CTCs
down-regulated the expression of epithelial biomarkers such as
cytokeratin, due to EMT. Discussion: We designed a novel
sensitive panel of antibodies that detected biomarker positive
CTCs which expressed ASGPR1, vimentin and cytokeratin
from peripheral blood samples, using imagestreamX.
1 Dent BM, Ogle LF, O'Donnell RL, Hayes N, Malik U,
Curtin NJ, Boddy AV, Plummer ER, Edmondson RJ,
Reeves HL, May FEB and Jamieson D: High-resolution
imaging for the detection and characterisation of
circulating tumour cells from patients with oesophageal,
hepatocellular, thyroid and ovarian cancers. Int J Cancer
138(1): 206-216, 2016.
2 Li J, Chen L, Zhang X, Zhang Y, Liu H, Sun B, Zhao L,
Ge N, Qian H, Yang Y, Wu M and Yin Z: Detection of
Circulating Tumor Cells in Hepatocellular Carcinoma
Using Antibodies against Asialoglycoprotein Receptor,
Carbamoyl Phosphate Synthetase 1 and Pan-Cytokeratin'.
PLoS ONE 9(4): e96185, 2014.
3 Ogle LF, Orr JG, Willoughby CE, Hutton C, McPherson S,
Plummer R, Boddy AV, Curtin NJ, Jamieson D and Reeves
HL: Imagestream detection and characterisation of
circulating tumour cells – a liquid biopsy for Hepatocellular
Carcinoma? J Hepatol 65(2): 305-313, 2016.
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